Cohance Lifesciences
COHANCENSE

Cohance Lifesciences

₹456.60-4.25 (0.92%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Livesquawk
Cohance Life saw a Rs 46.35 cr BSE block trade for 1,000,045 shares at Rs 463.5/share.
Livesquawk
Goldman Sachs maintains Buy on Cohance with a ₹500 target, citing weak Q1 in Pharma CDMO and Agrochemicals. Recovery is expected from Q2FY27, driven by commercial deliveries, operational normalization, and strategic expansion.
Livesquawk
Cohance Lifesciences reports Q1 consolidated net loss of ₹241M. The loss improved compared to ₹489M in the prior year (YoY).